Sports doping: Emerging designer and therapeutic β 2 -agonists
Clinica Chimica Acta, ISSN: 0009-8981, Vol: 425, Page: 242-258
2013
- 26Citations
- 94Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations26
- Citation Indexes26
- 26
- CrossRef23
- Captures94
- Readers94
- 94
Review Description
Beta 2 -adrenergic agonists, or β 2 -agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of β 2 -agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006–2012) literature concerning the development of novel β 2 -agonists molecules either by modifying the molecule of known β 2 -agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging β 2 -agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0009898113003008; http://dx.doi.org/10.1016/j.cca.2013.07.031; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84884327600&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/23954776; https://linkinghub.elsevier.com/retrieve/pii/S0009898113003008; https://dx.doi.org/10.1016/j.cca.2013.07.031
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know